SCHEMBL10166030

SCHEMBL10166030

Cc1c(C(=O)O)ccc2c1CC[C@@H]2NC(=O)c1cc(C(=O)NCc2cc(F)cc(OC(F)(F)F)c2)nc2c(F)cnn12

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 2/20 0.75
MMP3 P08254 2/20 0.75
MMP13 P45452 2/20 0.75
MMP8 P22894 1/20 0.52
MMP12 P39900 1/20 0.52
RIPK1 Q13546 9/20 0.40
PDE2A O00408 1/20 0.35
KLKB1 P03952 2/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
EPHX2 P34913 1/20 0.32
ADRB2 P07550 1/20 0.31
GLS O94925 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
DHODH Q02127 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8254047 0.93 ADAMTS4 (0.78) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10167204 0.93 ADAMTS4 (0.80) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL8255754 0.92 MMP13 (0.80) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL8256445 0.90 ADAMTS4 (0.80) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL8252919 0.90 MMP13 (0.83) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL8222933 0.88 MMP13 (0.80) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10166080 0.88 MMP13 (0.82) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL13161124 0.88 ADAMTS4 (0.70) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL8256129 0.87 ADAMTS4 (0.68) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10166350 0.86 ADAMTS4 (0.69) ADAMTS4MMP3MMP13MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.